KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $941000.0.

  • Bionano Genomics' Share-based Compensation fell 5726.61% to $941000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 5037.59%. This contributed to the annual value of $9.7 million for FY2024, which is 3585.45% down from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Share-based Compensation is $941000.0, which was down 5726.61% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Bionano Genomics' Share-based Compensation peaked at $6.1 million during Q3 2022, and registered a low of $371000.0 during Q1 2021.
  • In the last 5 years, Bionano Genomics' Share-based Compensation had a median value of $3.0 million in 2024 and averaged $3.2 million.
  • Per our database at Business Quant, Bionano Genomics' Share-based Compensation skyrocketed by 127520.22% in 2022 and then tumbled by 5818.82% in 2025.
  • Quarter analysis of 5 years shows Bionano Genomics' Share-based Compensation stood at $4.8 million in 2021, then rose by 14.1% to $5.5 million in 2022, then tumbled by 38.46% to $3.4 million in 2023, then plummeted by 42.59% to $1.9 million in 2024, then plummeted by 51.39% to $941000.0 in 2025.
  • Its Share-based Compensation was $941000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $1.6 million in Q1 2025.